| Overview |
| bsm-61622r-pe-cy5-100ul |
| Phospho-CRK (Tyr221) Recombinant Monoclonal Antibody, PE-Cy5 Conjugated |
| WB |
| Human |
| Specifications |
| PE-Cy5 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human CRK around the phosphorylation site of Y221 |
| Tyr221 |
| Monoclonal |
| Recombinant |
| IgG |
| Lot dependent |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 1398 |
| P46108 |
| Cytoplasm, Cell membrane |
| Adapter molecule crk; avian sarcoma virus CT10 (v-crk) oncogene homolog; CRK; CRKII; Proto-oncogene c-Crk. |
| The Crk-I and Crk-II forms differ in their biological activities. Crk-II has less transforming activity than Crk-I. Crk-II mediates attachment-induced MAPK8 activation, membrane ruffling and cell motility in a Rac-dependent manner. Involved in phagocytosis of apoptotic cells and cell motility via its interaction with DOCK1 and DOCK4. May regulate the EFNA5-EPHA3 signaling. |
| Application Dilution |
| WB |
1:300-5000 |
Powered by Bioz